Eric Topol@EricTopol𝕏#AHA26 @NEJM
nejm.org/doi/full/10.1056/NEJMoa2610676?query=featured_home…
The two trials are TRIUMPH-4 and TRIUMPH-1-OA, published in the New England Journal of Medicine as Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. They enrolled adults without diabetes who had painful knee osteoarthritis and a BMI of at least 27, and randomized them to once-weekly retatrutide or placebo.
The pain result is real and reasonably large. In the pooled analysis, about two-thirds of retatrutide users had at least a 50% reduction in knee pain, versus 38% on placebo (per Northwestern's release). Weight fell by 20.0% at 9 mg and 23.7% at 12 mg, versus 4.6% on placebo. Serious adverse events were more common on retatrutide, and the most common side effects were gastrointestinal.
The claim that the benefit is independent of weight loss is the part I'd check. Weight dropped a great deal in these trials, and the reports I found don't separate how much of the pain relief is due to weight loss and how much isn't. That question needs the paper's analysis, not the headline.
The lead investigators also say the big unknown is whether the drug slows joint damage enough to delay replacement surgery. People who needed a knee replacement were excluded, so the trials don't answer that.
Also discussed here:
- Lilly says retatrutide beat Novo's Ozempic in a diabetes study
- GLP-1 Drugs: What the Evidence Shows, Organ by Organ
- Does Stopping a GLP-1 Drug Raise Your Heart Risk?
